Tectonic Therapeutic (TECX) Depreciation & Amortization (CF) (2017 - 2026)
Tectonic Therapeutic (TECX) posted quarterly Depreciation & Amortization (CF) of $304000.0 for Q1 2026, down 15.56% year-over-year from $360000.0 in Q1 2025, and down 8.71% quarter-over-quarter from $333000.0 in Q4 2025.
Powered by 
Analysis
Tectonic Therapeutic (TECX) Depreciation & Amortization (CF) (2017 - 2026) Analysis & Trends
Tectonic Therapeutic (TECX) has reported Depreciation & Amortization (CF) for 10 consecutive years, with $304000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Depreciation & Amortization (CF) fell 15.56% year-over-year to $304000.0; the TTM figure through Mar 2026 stood at $1.3 million (down 18.98% YoY), while the FY2025 annual figure was $1.4 million, down 16.41% from the prior year.
- Depreciation & Amortization (CF) slipped to $304000.0 in Q1 2026 per TECX's latest filing, from $333000.0 in the prior quarter.
- Across five years, Depreciation & Amortization (CF) topped out at $508000.0 in Q4 2024 and bottomed at $289000.0 in Q2 2023.
- Historically, Depreciation & Amortization (CF) has averaged $359352.9 across 5 years, with a median of $342000.0 in 2025.
- Annual changes were most pronounced in 2022 — Depreciation & Amortization (CF) jumped 37.11% — and 2025, when it slumped 34.45%.
- Tectonic Therapeutic's Depreciation & Amortization (CF) stood at $335000.0 in 2022, then gained by 11.34% to $373000.0 in 2023, then soared by 36.19% to $508000.0 in 2024, then slumped by 34.45% to $333000.0 in 2025, then fell by 8.71% to $304000.0 in 2026.
- Business Quant data shows TECX's Depreciation & Amortization (CF) at $304000.0 in Q1 2026, $333000.0 in Q4 2025, and $342000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 56.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 123.70 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 40.52 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | Tectonic Therapeutic | 589.02 Mn | 589.02 Mn | - | 285,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 285,000.00 |
| Mar 31, 2026 | 304,000.00 |
| Dec 31, 2025 | 333,000.00 |
| Sep 30, 2025 | 342,000.00 |
| Jun 30, 2025 | 340,000.00 |
| Mar 31, 2025 | 360,000.00 |
| Dec 31, 2024 | 508,000.00 |
| Sep 30, 2024 | 424,000.00 |
| Jun 30, 2024 | 336,000.00 |
| Mar 31, 2024 | 377,000.00 |
| Dec 31, 2023 | 373,000.00 |
| Sep 30, 2023 | 371,000.00 |
| Jun 30, 2023 | 289,000.00 |
| Mar 31, 2023 | 328,000.00 |
| Dec 31, 2022 | 335,000.00 |
| Sep 30, 2022 | 336,000.00 |
| Jun 30, 2022 | 354,000.00 |
| Mar 31, 2022 | 399,000.00 |
| Dec 31, 2021 | 436,000.00 |
| Sep 30, 2021 | 374,000.00 |